Morgan Stanley commented on Edwards Lifesciences EW. In a research report published today, Morgan Stanley stressed that a number of research had worrying implications for transapical implants.
In the report, Morgan Stanley states, "While neither the analyses presented today at PCR nor the stroke data at AATS on May 9 indicate a link from transapical implants to adverse outcomes, physician concerns on the topic seem to be increasing. These signals are not present in the transfemoral data. Given that transapical implants account for roughly half the Sapien volume in Europe, this bears watching."
At the moment, Morgan Stanley has an Equal-weight rating on Edwards. On Tuesday, Edwards lost 0.92% of its value to close the day at $88.47.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsEdwards LifesciencesHealth CareHealth Care EquipmentMorgan Stanley
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in